Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
Publication/Presentation Date
11-2024
Volume
144
Issue
1
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Article
COinS
